An anti-aging composition containing ectoine and a preparation method and application thereof

Abstract

The application discloses a kind of anti-aging composition containing ikdoin and its preparation method and application in the field of cosmetic technology, and every 100 weight parts contains the following weight parts of raw materials: polyol 10-30 parts, alkyl glycoside modified silicon dioxide 2-4 parts, skin conditioner 3-10 parts, phospholipid 2-6 parts, oil phase 2-5 parts, emulsifier 2-4 parts, and the balance is deionized water;By the synergistic compatibility of ikdoin and active ingredients such as edifenozide, the composition has strong antioxidant capacity, can effectively neutralize environmental oxidative stress, reduce oxidative damage, and further delay the process of skin photoaging;The composition has excellent anti-inflammatory efficacy, can effectively reduce inflammatory response;In addition, through the innovative design of nano-carrier-alkyl glycoside modified silicon dioxide, not only the physical stability of the system is improved, but also the composition obtains excellent long-acting moisturizing capacity, and the transdermal absorption and efficacy of active ingredients are enhanced, and has wide application prospect in the field of external use cosmetics.

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to an anti-aging composition containing ectoine, its preparation method, and its application. Background Technology

[0002] Ectoine (1,4,5,6-tetrahydro-2-methyl-4-carboxylic acid) is a small-molecule amino acid derivative. Ectoine can be obtained through chemical synthesis and bio-fermentation. However, the high cost and potential environmental pollution associated with chemical synthesis make it less advantageous for industrial production. Therefore, bio-fermentation, with its high efficiency and environmental benefits, has become the primary method for producing ectoine.

[0003] Ectoine plays multiple roles in the field of active pharmaceutical ingredients (APIs). For example, it can be used as a functional excipient in drug formulations. Furthermore, studies have shown that ectoine has potential medicinal value in the field of neurodegenerative diseases. Ectoine also has promising applications in drug development due to its ability to form a hydration layer around biomolecules, protecting the structure and function of cells and biomolecules. Therefore, ectoine is currently widely used as a high-value compound in cosmetics, pharmaceuticals, and food. However, antioxidation is a crucial mechanism for anti-aging. Oxidative stress caused by free radicals is a key factor in skin aging. By scavenging free radicals, oxidative stress damage to cells can be reduced, maintaining the integrity and function of cell membranes, slowing down the cellular aging process, and extending cell lifespan. In addition, antioxidants can reduce inflammatory responses and promote tissue repair. Idebenone is a natural antioxidant that can directly react with free radicals, converting them into stable compounds, thereby reducing free radical damage to cells and tissues. Currently, the efficacy of ectoine in skincare products is mainly focused on accelerating stratum corneum repair and reducing stress responses caused by external stimuli, rather than on scavenging free radicals. Furthermore, there are no reports on the combined use of idebenone and ectoine for anti-aging effects. In addition, idebenone has poor stability and low permeability and absorption in the skin, which may limit its skincare effects. Therefore, in research on the combined use of these two products, maintaining the stability of idebenone in cosmetics, promoting its penetration into the skin, and effectively maximizing the efficacy of both idebenone and ectoine are technical challenges that need to be addressed.

[0004] To address the aforementioned technical problems, this invention provides an anti-aging composition containing ectoine, its preparation method, and its application. Summary of the Invention

[0005] The purpose of this invention is to solve the above-mentioned technical problems by providing an anti-aging composition containing ectoine, its preparation method, and its application.

[0006] The present invention achieves the above objectives through the following technical solutions:

[0007] As a first aspect of the present invention, an anti-aging composition containing ectoine is provided, comprising, per 100 parts by weight, the following raw materials in parts by weight: 10-30 parts of polyol, 2-4 parts of alkyl glycoside modified silica, 3-10 parts of skin conditioning agent, 2-6 parts of phospholipid, 2-5 parts of oil phase, 2-4 parts of emulsifier, and the balance being deionized water; wherein the skin conditioning agent is at least one of ectoine or idebenone.

[0008] As a further optimization of the present invention, the polyol is at least two of glycerol, propylene glycol or 1,3-butanediol.

[0009] As a further optimization of the present invention, the oil phase is at least one of squalane, jojoba oil or polydimethylsiloxane.

[0010] As a further optimization of the present invention, the emulsifier is at least one of cetearyl alcohol polyether, sucrose stearate or cocoyl glucoside.

[0011] As a further optimization of the present invention, the phospholipid is at least one of soybean lecithin, hydrogenated lecithin, or phosphatidylcholine.

[0012] As a further optimized embodiment of the present invention, alkyl glycosides and hydroxylated silica are added to ethyl acetate and reacted in a constant temperature water bath at 30-60°C with stirring at 100-300 r / min for 2-4 h to obtain alkyl glycoside modified silica; wherein the alkyl carbon chain length of the alkyl glycoside is 8-14, and the mass ratio of hydroxylated silica to alkyl glycoside is 1-3:1.

[0013] As a further optimization of the present invention, the skin conditioning agent is a mixture of ectoine and idebenone, with a ratio of 1-4:1.

[0014] As a second aspect of the invention, the use of an anti-aging composition containing ectoine as described above in the preparation of cosmetics is also provided.

[0015] As a third aspect of the present invention, a method for preparing an anti-aging composition containing ectoine as described in any of the above-described embodiments is also provided, comprising the following steps:

[0016] (1) Add the prescribed amounts of ectoine and idebenone to the polyol, and sonicate at 25-30℃ for 30-60 min to disperse them fully, to obtain phase A;

[0017] (2) Add the prescribed amount of emulsifier and phospholipid to the oil phase, and magnetically stir at 200-500 rpm for 30-60 min to obtain phase B;

[0018] (3) First, add phase A to water and stir at 40-60℃ for 30-60 minutes. Then, add phase B under shear conditions and mix well. Finally, use high-pressure microchannel multiphase flow technology to obtain an anti-aging composition containing ectoin.

[0019] As a further optimization of the present invention, in step (3), the shearing speed is 4000-6000 rpm, the shearing temperature is 50-60℃, and the shearing time is 5-10 min; the pressure of the high-pressure microchannel technology is 40-60 MPa, and the homogenization times are 2-4 times.

[0020] The beneficial effects of this invention are as follows:

[0021] This invention utilizes the synergistic combination of ectoine and idebenone, two active ingredients, to create a composition with potent antioxidant capabilities. The DPPH free radical scavenging rate reaches 95.3-97.4%, effectively neutralizing environmental oxidative stress, reducing oxidative damage, and thus delaying the photoaging process of the skin. Furthermore, the composition exhibits excellent anti-inflammatory effects, with a hyaluronidase inhibition rate of up to 87.5%, effectively reducing inflammatory responses and maintaining skin elasticity and firmness. In addition, the innovative design of the nanocarrier—alkyl glycoside-modified silica—not only improves the physical stability of the system but also gives the composition excellent long-lasting moisturizing capabilities, while enhancing the transdermal absorption and efficacy of the active ingredients. Finally, the ectoine-containing anti-aging composition provided by this invention is mild and stable, has a simple preparation process, is non-irritating to the skin, and has high safety, showing broad application prospects in the field of topical cosmetics. Attached Figure Description

[0022] Figure 1 The HPLC chromatogram of ectoine provided by this invention. Detailed Implementation

[0023] The present application will now be described in further detail. It should be noted that the following specific embodiments are only used to further illustrate the present application and should not be construed as limiting the scope of protection of the present application. Those skilled in the art can make some non-essential improvements and adjustments to the present application based on the above application content.

[0024] Unless otherwise specified, all reagents and materials used below are commercially available products, and all methods used below are conventional methods known to those skilled in the art.

[0025] 1. Biosynthesis of Ectoin

[0026] Ecdoline can be obtained commercially or synthesized using the following biosynthetic method, the specific steps of which are as follows:

[0027] (1.1) Using an inoculation loop, pick up 3-5 single colonies of the marine salt-tolerant bacterium Brevibacterium sp. JCM 6894 growing on a plate medium and inoculate them into a mixed medium. Incubate at 30°C for 2 days in a shake flask to obtain a bacterial suspension.

[0028] The plate culture medium consisted of the following components: glucose 12 g / L, yeast extract 6 g / L, NaCl 22 g / L, KCl 1.2 g / L, MgSO4·7H2O 0.6 g / L, vitamin B1 0.01 g / L, agar 20 g / L, and pH 7.4.

[0029] The mixed culture medium consists of the following components: peptone 5.0 g / L, yeast extract 1.0 g / L, MgSO4·7H2O 0.7 g / L, NH4Cl 1.0 g / L, CaCl2·2H2O 0.1 g / L, K2PO4 0.035 g / L, and KH2PO4 0.015 g / L. The pH of the mixed culture medium is adjusted to 7.5.

[0030] (1.2) Inoculate the bacterial suspension into a 50L or 100L seed tank at a 1% inoculation rate and incubate at 30℃ for 3 days, or inoculate into a 1000L fermenter at a 5% inoculation rate and incubate at 30℃ for 2 days. Then, incubate in a medium containing 3M NaCl at 30℃ for 2 days. Centrifuge to obtain bacterial cakes. Use the osmotic pressure drop extraction method to suspend the bacterial cakes in pure water and use osmotic pressure to release the ectoin accumulated in the cells into the solution. Centrifuge at 30℃ for 1 hour and retain the supernatant.

[0031] (1.3) The supernatant was subjected to X-5 type macroporous adsorption resin chromatography column (diameter 50cm, height 200cm, resin packing volume 400L), the temperature was controlled at 45℃, the flow rate was 1.5BV / h (BV is column volume, i.e. 400L / h), the adsorption time was 2h, and the decolorized filtrate was collected.

[0032] (1.4) The filtrate was transferred to a crystallization tank, cooling water was introduced, the temperature was lowered to 4℃, and the crystallization was allowed to stand for 18h. A large number of white needle-like crystals were observed to precipitate. The crystallization liquid was filtered through a plate and frame filter press (0.22μm filter cloth), the crystals were collected, and transferred to a vacuum drying oven. The temperature was controlled at 60℃ and the vacuum degree was 0.092MPa. The crystals were dried for 10h to obtain dried ectoine crystals.

[0033] (1.5) The dried ectoine crystals obtained in the above steps were analyzed by Shimadzu HPLC. An SB-C18 column (250 mm × 4.6 mm, 5 μm, Agilent Technologies) was used. The mobile phase was water:acetonitrile (98:2, v / v), the flow rate was constant at 0.5 mL / min, the column temperature was 30 °C, the detector was SPD-20AV, and the UV detection wavelength was 210 nm. The HPLC chromatogram of ectoine is shown below. Figure 1 As shown.

[0034] 2. Preparation of anti-aging compositions containing ectoine

[0035] 2.1 Formulation Design

[0036] The formulations of the anti-aging composition containing ectoine (hereinafter referred to as the anti-aging composition) are shown in Table 1.

[0037] Table 1 Formulations of anti-aging compositions YP-1 to YP-6 (based on 100 parts by weight)

[0038]

[0039] Note: "-" in the table indicates that it has not been added.

[0040] To investigate the effect of skin conditioning agent design in anti-aging compositions containing ectoine on the efficacy of the anti-aging compositions, the formulation of anti-aging composition YP-1 was adjusted as shown in Table 2, and these were designated as anti-aging compositions DZ-1 to DZ-4.

[0041] Table 2 Formulations of the control anti-aging compositions DZ-1 to DZ-4 (based on 100 parts by weight)

[0042]

[0043] The preparation method of C12-alkyl glycoside modified silica in the formulations of anti-aging compositions YP-1 to YP-6 and control anti-aging compositions DZ-1 to DZ-4 is as follows:

[0044] First, nano-silica (particle size range of 5-10nm) is immersed in 30wt% hydrogen peroxide solution, reacted at 60℃ for 90min, washed to remove hydrogen peroxide, and dried to obtain hydroxylated silica.

[0045] Then, according to the mass ratio of hydroxylated silica to alkyl glycoside of 2:1, hydroxylated silica and alkyl glycoside are added to ethyl acetate and reacted in a constant temperature water bath at 40℃ with stirring at 300 r / min for 2 h to obtain alkyl glycoside modified silica; wherein, the alkyl carbon chain length of the alkyl glycoside is 12 (i.e., C12-alkyl glycoside).

[0046] To investigate the effect of adding alkyl glycoside-modified silica to the anti-aging composition containing ectoine on the anti-aging composition, further adjustments were made to the formulation of the anti-aging composition YP-1 as follows:

[0047] Anti-aging composition DZ-5: C10-alkyl glycoside modified silica is used instead of C12-alkyl glycoside modified silica. The preparation method of C10-alkyl glycoside modified silica is the same as that of C12-alkyl glycoside modified silica, except that C10-alkyl glycoside is used instead of 12-alkyl glycoside.

[0048] Anti-aging composition DZ-6: C14-alkyl glycoside modified silica replaces C12-alkyl glycoside modified silica. The preparation method of C14-alkyl glycoside modified silica is the same as that of C12-alkyl glycoside modified silica, except that C14-alkyl glycoside is replaced by C12-alkyl glycoside.

[0049] Anti-aging composition DZ-7: C12-alkyl glycoside modified silica is replaced with the same amount of unmodified silica in the formulation.

[0050] Anti-aging composition DZ-8: PEG-400 modified silica replaces C12-alkyl glycoside modified silica. The preparation method of PEG400 modified silica is as follows: first, nano silica (particle size range of 5-10 nm) is immersed in 30wt% hydrogen peroxide solution and reacted at 60℃ for 90 min. After washing to remove hydrogen peroxide, it is dried to obtain hydroxylated silica. According to the mass ratio of hydroxylated silica to PEG-400 of 2:1, hydroxylated silica and PEG-400 are added to ethyl acetate and reacted in a constant temperature water bath at 40℃ with stirring at 300 r / min for 2 h to obtain the final product.

[0051] Anti-aging composition DZ-9: The addition of C12-alkyl glycoside modified silica is omitted.

[0052] 2.2 Preparation Method

[0053] The anti-aging compositions YP-1 to YP-6 and the control anti-aging compositions DZ-1 to DZ-9 were prepared according to the following steps: (1) Add the prescribed amount of ectoine and / or idebenone to a polyol and sonicate at 25°C for 60 min to obtain phase A; (2) Add the prescribed amount of emulsifier and phospholipid to the oil phase and magnetically stir at 500 rpm for 30 min to obtain phase B; (3) First add phase A to water and stir at 60°C for 30 min. Then, under the shearing conditions of 6000 rpm, 50°C, and 5 min, add phase B and mix well. The anti-aging composition is obtained by using high-pressure microchannel multiphase flow technology, wherein the pressure of high-pressure microchannel technology is 60 MPa and the number of homogenization times is 2.

[0054] 3. Functional testing of anti-aging compositions

[0055] (1) In vitro antioxidant test (DPPH free radical method)

[0056] In vitro antioxidant tests were conducted on anti-aging compositions YP-1 to YP-6 and control anti-aging compositions DZ-1 to DZ-4. DPPH· is a nitrogen-centered stable free radical, and its anhydrous ethanol solution showed maximum absorption at a wavelength of 517 nm. In the presence of free radical scavengers, DPPH· can be bound to or replaced, reducing the number of free radicals and thus decreasing absorbance. A blank control group was also included, which was based on the YP-1 anti-aging composition formulation but without the addition of skin conditioning agents.

[0057] First, weigh DPPH and dilute it to 250 mL in a brown volumetric flask with anhydrous ethanol to prepare 2 × 10⁻⁶ ppm. -4 Store the mol / L DPPH solution in a refrigerator protected from light.

[0058] Then, take 4.0 mL of 2×10 -4 After mixing and stabilizing a 1.0 mL solution of 2 × 10⁻⁶ DPPH solution with 1.0 mL of 95% ethanol, the absorbance was measured at 515 nm using 95% ethanol as a reference, and recorded as A0. Then, 4.0 mL of 95% ethanol and 1.0 mL of the test sample solution (anti-aging compositions YP-1 to YP-6, and control anti-aging compositions DZ-1 to DZ-4) were mixed and stabilized. The absorbance was measured at 515 nm using 95% ethanol as a reference, and recorded as A1. Finally, 4.0 mL of 2 × 10⁻⁶ DPPH solution was mixed and stabilized. -4 After mixing 1.0 mL of mol / L DPPH solution and the test sample and allowing the reaction to stabilize, the absorbance was measured at 515 nm using 95% ethanol as a reference, and recorded as A2.

[0059] Calculate the DPPH removal rate using the following formula:

[0060] DPPH clearance rate (100%) = [1 - (A2 - A1) / A0] × 100%.

[0061] The results are shown in Table 3.

[0062] Table 3 Results of in vitro antioxidant tests

[0063]

[0064] Antioxidation is one of the important mechanisms of anti-aging. Oxidative stress caused by free radicals is a key factor in skin aging. Neutralizing free radicals and reducing oxidative damage can delay skin aging. As shown in Table 3, compared with the blank control group, the addition of skin conditioning agents edokine and idebenone can significantly increase the DPPH free radical scavenging rate of the composition, and the rate increases with the amount added. In addition, under the premise of a certain amount of skin conditioning agent formulation, the DPPH free radical scavenging rate of the composition is slightly higher when edokine and idebenone are added together than when edokine and idebenone are added alone. The combined addition of the two can enable the composition to exert excellent antioxidant protection and give the composition a certain anti-aging effect.

[0065] (2) Hyaluronidase activity inhibition experiment

[0066] Hyaluronidase activity inhibition experiments were conducted on anti-aging compositions YP-1 to YP-6 and control anti-aging compositions DZ-1 to DZ-4. Hyaluronidase is involved in type I hypersensitivity reactions and is strongly correlated with inflammation and allergies. Therefore, inhibiting hyaluronidase activity is used as an indicator for studying anti-allergic effects.

[0067] The experimental system for inhibiting hyaluronidase activity is set up as shown in Table 4.

[0068] Table 4. Experimental setup for hyaluronidase activity inhibition

[0069]

[0070] In Table 4, the acetate buffer solution is prepared by dissolving 11.55 ml of glacial acetic acid in 1000 ml of distilled water to obtain solution A; dissolving 27.2 g of sodium acetate trihydrate in 1000 ml of distilled water to obtain solution B; and mixing and diluting 48 ml of solution A and 45.2 ml of solution B to a final volume of 1 L to prepare an acetate buffer solution with a pH of 5.6. Hyaluronidase is prepared by weighing 16.5 mg... 303 U / mg hyaluronidase: Dissolve in 10 ml volumetric flask with acetate buffer and dilute to the mark; ready to use immediately. Sodium hyaluronate: Weigh 50 mg sodium hyaluronate and dissolve in 100 ml volumetric flask with acetate buffer and dilute to the mark. Acetylacetone solution: Mix 50 ml of 1.0 mol / L sodium carbonate solution and 3.5 ml of acetylacetone solution thoroughly; ready to use immediately. p-Dimethylaminobenzaldehyde P-DMAB (color reagent): Dissolve 0.8 g of p-dimethylaminobenzaldehyde in 15 ml of concentrated hydrochloric acid and 15 ml of anhydrous ethanol and mix thoroughly. CaCl2 solution: Weigh 27.75 g of CaCl2 and dissolve in 100 ml volumetric flask with distilled water and dilute to the mark. NaOH solution: Weigh 20 g of NaOH and dissolve in 100 ml volumetric flask with distilled water and dilute to the mark.

[0071] Add the corresponding test solution to the test tube as shown in Table 4, shake thoroughly, incubate at 30°C for 30 min, transfer to a 96-well plate, and measure the absorbance at 530 nm; the hyaluronidase inhibition rate is calculated according to the formula:

[0072] ;

[0073] In the formula, a is the OD value of the sample solution (hyaluronidase, sample, and sodium hyaluronate);

[0074] b is the OD value of the blank sample (acetic acid buffer, sample, and acetate buffer);

[0075] c represents the OD value of the control solution (hyaluronidase, deionized water, and sodium hyaluronate).

[0076] d represents the OD value of the control blank (acetic acid buffer, deionized water, and acetate buffer).

[0077] The results are shown in Table 5.

[0078] Table 5 Results of Hyaluronidase Activity Inhibition Experiment

[0079]

[0080] As shown in Table 5, compared with the blank control group, the addition of skin conditioning agents edokine and idebenone significantly enhanced the composition's hyaluronidase inhibitory ability. Under the premise of a fixed amount of skin conditioning agents, the composition's hyaluronidase inhibitory ability was higher when edokine and idebenone were added together than when edokine and idebenone were added alone. The combined addition of the two agents enabled the composition to exert a more superior hyaluronidase inhibitory ability, resulting in better anti-inflammatory effects.

[0081] (3) Security testing

[0082] Thirty participants were selected for the experiment, referencing the 2015 edition of the "Cosmetic Safety Technical Specifications". The area selected did not exceed 50mm². 2 A qualified patch test apparatus with a depth of approximately 1 mm is used. The test substance is placed in the small chamber of the patch test apparatus, with a volume of approximately 0.020-0.025 mL (liquid). The test substance is an anti-aging composition YP-1 to YP-6 diluted to 1%. The control well uses the same diluent for the anti-aging composition. The patch test apparatus containing the test substance is applied to the back or flexor side of the forearm of the subject using hypoallergenic adhesive tape. Gently press with the palm of the hand to ensure even application to the skin, and leave for 24 hours. Skin reactions are observed according to the grading criteria for closed patch tests at 30 minutes (after the indentation disappears), 24 hours, and 48 hours after removing the patch test apparatus.

[0083] The grading criteria for skin reactions in the closed patch test are shown in Table 6, and the observation results should be recorded.

[0084] Table 6. Grading Criteria for Skin Reactions in Closed Patch Tests

[0085]

[0086] The results are shown in Table 7. The anti-aging compositions YP-1 to YP-6 are all non-irritating to the skin and have high safety, and can be used in cosmetics, skin care products and other topical skin preparations.

[0087] Table 7 Patch Test Results

[0088]

[0089] (4) Moisturizing efficacy test

[0090] Moisturizing efficacy tests were conducted on anti-aging composition YP-1 and control anti-aging compositions DZ-5 to DZ-9. 3 ml of each sample solution was evenly coated onto a glass plate covered with 3M tape and placed in an environment with a relative humidity (RH) of 43% for 72 hours to maintain constant weight. Afterward, the samples were transferred to a desiccator containing 200 g of dry silica gel and placed for 4, 8, and 12 hours, respectively, before weighing. The moisturizing rate was calculated using the following formula:

[0091] ;

[0092] Where m0 is the moisture mass before placement; m1 is the moisture mass after placement for a period of time.

[0093] The results are shown in Table 8.

[0094] Table 8 Results of Moisturizing Efficacy Tests

[0095]

[0096] As shown in Table 8, compared with other groups, DZ-6 had a higher moisturizing rate in the 4-12h period, remaining close to 50% after 12h, while DZ-9 had the worst moisturizing rate in the 4-12h period, only 30.5% after 12h. This indicates that the addition of alkyl glycoside-modified silica to the composition helps improve its moisturizing effect. Furthermore, the table shows that the moisturizing effect of the composition increases with the length of the alkyl glycoside carbon chain, and is superior to the effect of the conventional surfactant PEG-400.

[0097] (5) Stability evaluation

[0098] The initial particle size of anti-aging composition YP-1 and control anti-aging compositions DZ-5 to DZ-9 was determined using a Malvern particle size analyzer. Then, anti-aging composition YP-1 and control anti-aging compositions DZ-5 to DZ-9 were placed in different sealed containers and incubated at 4°C, room temperature, and 40°C for 90 days each. Afterward, the compositions were removed and allowed to recover to room temperature for 30 minutes before particle size analysis using the Malvern particle size analyzer. Before analysis, the samples were diluted 10-fold and tested according to preset parameters and procedures. The retention rate of the active ingredient was then calculated. Specifically, the active ingredient was separated from the sample by centrifugation and ultrafiltration, and the corresponding mobile phase was prepared according to the requirements of HPLC analysis and the properties of the active ingredient. Conditions were optimized to obtain better separation effect and sensitivity. The concentration of the active ingredient in the sample was calculated, and standard solutions of the same concentration were prepared.

[0099] Inject the standard solutions sequentially into the HPLC instrument, record the peak areas, and establish a standard curve against the concentration. Inject the test sample solution into the HPLC instrument and record the peak areas. Calculate the content of the active ingredient based on the standard curve.

[0100] Active ingredient retention rate = (initial active ingredient content - current active ingredient content) / initial active ingredient content × 100%;

[0101] The results are shown in Table 9.

[0102] Table 9 Stability Evaluation

[0103]

[0104] Note: The active ingredients are the sum of ectoine and idebenone.

[0105] As shown in Table 9, the particle size of anti-aging composition YP-1 is relatively small, around 10 nm. Furthermore, after being placed at 4℃, room temperature, and 40℃ for 90 days, the particle size changed significantly. Adjusting the carbon chain length of the alkyl glycosides used in the alkyl glycoside-modified silica, it can be seen that anti-aging compositions DZ-5 and DZ-6 showed no significant difference compared to anti-aging composition YP-1. However, when unmodified silica was used to replace the C12-alkyl glycoside-modified silica in anti-aging composition YP-1, the particle size of DZ-7 was clearly larger than that of YP-1. This demonstrates that C12-alkyl glycoside-modified silica has a positive effect on controlling the particle size of the compositions. Correspondingly, the particle size of DZ-8, which uses the conventional surfactant PEG-400 to modify silica, is also significantly larger than that of anti-aging composition YP-1. For topical products, smaller particle sizes allow for easier penetration through the skin barrier, enabling active ingredients to quickly and effectively penetrate deep into the skin and maximizing their efficacy.

[0106] Furthermore, after 90 days of storage at 4℃, room temperature, and 40℃, the active ingredient retention rate of anti-aging composition YP-1 remained above 92%-95%, demonstrating good stability. Adjusting the carbon chain length of the alkyl glycosides used in the alkyl glycoside-modified silica, it can be seen that the stability of anti-aging compositions DZ-5 and DZ-6 did not show a significant difference compared to anti-aging composition YP-1. However, after 90 days of storage at 4℃, room temperature, and 40℃, the active ingredient retention rates of anti-aging compositions DZ-7, DZ-8, and DZ-9 were less than 90%. This indicates that the addition of alkyl glycoside-modified silica to anti-aging compositions can effectively retain the active ingredients, thereby ensuring the stable efficacy of the compositions.

[0107] The embodiments described above are merely examples of several implementations of the present invention, and while the descriptions are specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that those skilled in the art can make various modifications and improvements without departing from the concept of the present invention, and these modifications and improvements all fall within the scope of protection of the present invention.

Claims

1. An anti-aging composition containing ectoine, characterized in that: Each 100 parts by weight contains the following raw materials: 10-30 parts polyol, 2-4 parts alkyl glycoside modified silica, 3-10 parts skin conditioning agent, 2-6 parts phospholipid, 2-5 parts oil phase, 2-4 parts emulsifier, and the balance is deionized water. The skin conditioning agent is a mixture of ectoine and idebenone, with a ratio of 1-4:

1. The alkyl glycoside modified silica is obtained by adding alkyl glycoside and hydroxylated silica to ethyl acetate and stirring in a constant temperature water bath at 30-60℃ for 2-4 hours at 100-300 r / min; wherein the alkyl carbon chain length of the alkyl glycoside is 8-14, and the mass ratio of hydroxylated silica to alkyl glycoside is 1-3:

1.

2. The anti-aging composition containing ectoine according to claim 1, characterized in that, The polyol is at least two of glycerol, propylene glycol, or 1,3-butanediol.

3. The anti-aging composition containing ectoine according to claim 1, characterized in that, The oil phase is at least one of squalane, jojoba oil, or polydimethylsiloxane.

4. The anti-aging composition containing ectoine according to claim 1, characterized in that, The emulsifier is at least one of cetearyl alcohol polyether, sucrose stearate or cocoyl glucoside.

5. The anti-aging composition containing ectoine according to claim 1, characterized in that, The phospholipid is at least one of soybean lecithin, hydrogenated lecithin, or phosphatidylcholine.

6. The use of an anti-aging composition containing ectoine as described in any one of claims 1-5 in the preparation of cosmetics.

7. A method for preparing an anti-aging composition containing ectoine as described in any one of claims 1-5, characterized in that, Includes the following steps: (1) Add the prescribed amounts of ectoine and idebenone to the polyol and sonicate at 25-30℃ for 30-60 min to disperse them fully, thereby obtaining phase A; (2) Add the prescribed amount of emulsifier and phospholipid to the oil phase, and magnetically stir at 200-500 rpm for 30-60 min to obtain phase B; (3) First, add phase A to water and stir at 40-60℃ for 30-60 minutes. Then, add phase B under shear conditions and mix well. Finally, use high-pressure microchannel multiphase flow technology to obtain an anti-aging composition containing ectoin.

8. The method for preparing the anti-aging composition containing ectoine according to claim 7, characterized in that, In step (3), the shearing speed is 4000-6000 rpm, the shearing temperature is 50-60℃, and the shearing time is 5-10 min; the pressure of the high-pressure microchannel multiphase flow technology is 40-60 MPa, and the homogenization times are 2-4 times.

Images